HYD Stock Overview
Provides product design, engineering, and regulatory consulting services in Australia, Singapore, Europe, North America, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Hydrix Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.014 |
52 Week High | AU$0.04 |
52 Week Low | AU$0.012 |
Beta | 1.65 |
11 Month Change | -12.50% |
3 Month Change | -26.32% |
1 Year Change | -46.15% |
33 Year Change | -92.00% |
5 Year Change | -95.63% |
Change since IPO | -97.94% |
Recent News & Updates
Recent updates
Shareholder Returns
HYD | AU Electronic | AU Market | |
---|---|---|---|
7D | 7.7% | 0.9% | -0.3% |
1Y | -46.2% | 24.9% | 8.3% |
Return vs Industry: HYD underperformed the Australian Electronic industry which returned 24.9% over the past year.
Return vs Market: HYD underperformed the Australian Market which returned 8.3% over the past year.
Price Volatility
HYD volatility | |
---|---|
HYD Average Weekly Movement | 21.1% |
Electronic Industry Average Movement | 9.9% |
Market Average Movement | 8.2% |
10% most volatile stocks in AU Market | 16.3% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: HYD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine HYD's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 70 | n/a | www.hydrix.com |
Hydrix Limited provides product design, engineering, and regulatory consulting services in Australia, Singapore, Europe, North America, and internationally. The company operates through three segments: Hydrix Services, Hydrix Medical, and Hydrix. Its products portfolio comprises The GUARDIAN, a cardiac monitoring device that alerts and warns patients to seek medical attention for acute coronary syndrome (ACS), including silent heart attacks; LUDO, a customizable plug-and-play platform that offers critical tools to start MCS pump development; EchoSolv, a cloud-based decision support platform, which provides physicians with tools to identify patients at-risk of structural heart disease; and Implicity, an AI-driven RM solution that delivers cardiovascular monitoring technology and data management tools, which supports health professionals in the diagnosis, rehabilitation, and surveillance of cardiovascular patients.
Hydrix Limited Fundamentals Summary
HYD fundamental statistics | |
---|---|
Market cap | AU$3.56m |
Earnings (TTM) | -AU$2.23m |
Revenue (TTM) | AU$12.66m |
0.3x
P/S Ratio-1.6x
P/E RatioIs HYD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HYD income statement (TTM) | |
---|---|
Revenue | AU$12.66m |
Cost of Revenue | AU$1.04m |
Gross Profit | AU$11.62m |
Other Expenses | AU$13.85m |
Earnings | -AU$2.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0088 |
Gross Margin | 91.76% |
Net Profit Margin | -17.61% |
Debt/Equity Ratio | 151.4% |
How did HYD perform over the long term?
See historical performance and comparison